title: The risk of cutaneous adverse reactions among patients with the HLA-A* 31:01 allele who are given carbamazepine, oxcarbazepine or eslicarbazepine: a perspective review.
abstract: Carbamazepine is a drug that is widely used for the treatment of epilepsy, trigeminal neuralgia and bipolar disorder. This drug is also known to cause cutaneous adverse drug reactions (cADRs) in up to 10% of patients. The recent progress in pharmacogenetics has revealed that human leukocyte antigen (HLA) genotypes are associated with a susceptibility to the cADRs caused by particular drugs. For carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis, very strong associations with HLA-B*15:02 have been found mainly in patients of Southeastern Asian origin. In some countries, prescreening HLA-B*15:02 allele has already been put to practical use as a biomarker to avoid the life-threatening adverse drug reactions. In this review, another risk factor for carbamazepine-induced cADRs is discussed, namely HLA-A*31:01. We compare the strength of the association between HLA-A*31:01 and carbamazepine-induced cADRs based on reports for various ethnic populations; discuss the difference between the HLA-A*31:01 and HLA-B*15:02 biomarkers and the usefulness of prescreening HLA-A*31:01 to detect patients at high risk for carbamazepine-induced cADRs; and refer to points that remain to be resolved.
authors.affiliation: Senior Researcher, Division of Medicinal Safety Science, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan.
authors.forename: Nahoko
authors.initials: N
authors.lastname: Kaniwa
authors.affiliation: Director, Division of Medicinal Safety Science, National Institute of Health Sciences, Tokyo, Japan.
authors.forename: Yoshiro
authors.initials: Y
authors.lastname: Saito
keywords: Biomarker; HLA genotype; Stevens–Johnson syndrome; hypersensitivity syndrome; toxic epidermal necrolysis
references.citation: Epilepsia. 2010 May;51(5):818-29
references.pmid: 20132298
references.citation: Eur J Neurol. 2008 May;15(5):e43
references.pmid: 18355308
references.citation: Epilepsy Res. 2011 Nov;97(1-2):190-7
references.pmid: 21917426
references.citation: J Dermatol. 2008 Oct;35(10):683-5
references.pmid: 19017052
references.citation: Seizure. 2011 Jul;20(6):446-8
references.pmid: 21397523
references.citation: N Engl J Med. 2011 Mar 24;364(12):1126-33
references.pmid: 21428768
references.citation: Epilepsia. 2010 May;51(5):926-30
references.pmid: 20345939
references.citation: Epilepsia. 2010 Dec;51(12):2461-5
references.pmid: 21204807
references.citation: Nucleic Acids Res. 2011 Jan;39(Database issue):D1171-6
references.pmid: 21071412
references.citation: J Dermatol. 2012 Jul;39(7):594-601
references.pmid: 22211527
references.citation: J Allergy Clin Immunol. 2011 Dec;128(6):1266-1276.e11
references.pmid: 21924464
references.citation: N Engl J Med. 2011 Mar 24;364(12):1134-43
references.pmid: 21428769
references.citation: Pain Pract. 2012 Mar;12(3):202-8
references.pmid: 21676164
references.citation: Epilepsy Behav. 2008 Jul;13(1):156-61
references.pmid: 18331816
references.citation: Hepatology. 2013 Feb;57(2):727-39
references.pmid: 22987284
references.citation: Hum Mol Genet. 2011 Mar 1;20(5):1034-41
references.pmid: 21149285
references.citation: Pharmacogenet Genomics. 2006 Apr;16(4):297-306
references.pmid: 16538176
references.citation: Seizure. 2011 Mar;20(2):160-2
references.pmid: 21169036
references.citation: J Allergy Clin Immunol. 2012 Jun;129(6):1562-9.e5
references.pmid: 22322005
references.citation: Eur J Clin Pharmacol. 2011 Sep;67(9):885-7
references.pmid: 21424386
references.citation: Pharmacogenomics J. 2006 Jul-Aug;6(4):265-8
references.pmid: 16415921
references.citation: Epilepsia. 2008 Dec;49(12):2087-91
references.pmid: 18637831
references.citation: Clin Pharmacol Ther. 2013 Jul;94(1):142-9
references.pmid: 23588310
references.citation: Br J Clin Pharmacol. 2011 May;71(5):701-7
references.pmid: 21480949
references.citation: Clin Pharmacol Ther. 2012 Dec;92(6):757-65
references.pmid: 23132554
references.citation: Indian J Dermatol Venereol Leprol. 2009 Nov-Dec;75(6):579-82
references.pmid: 19915237
references.citation: Arch Dermatol. 1993 Jan;129(1):92-6
references.pmid: 8420497
references.citation: Proteomics Clin Appl. 2009 Jun;3(6):720-9
references.pmid: 21136982
references.citation: Mol Pharmacol. 2003 Mar;63(3):732-41
references.pmid: 12606784
references.citation: Drug Metab Pharmacokinet. 2013;28(5):435-8
references.pmid: 23399568
references.citation: Drug Metab Pharmacokinet. 2012;27(1):9-54
references.pmid: 22123129
references.citation: Pharmacogenomics. 2010 Mar;11(3):349-56
references.pmid: 20235791
references.citation: Seizure. 2012 Oct;21(8):614-8
references.pmid: 22818943
references.citation: Epilepsia. 2007 May;48(5):1015-8
references.pmid: 17509004
references.citation: Nature. 2004 Apr 1;428(6982):486
references.pmid: 15057820
references.citation: Pharmacogenet Genomics. 2012 Jun;22(6):441-6
references.pmid: 22453764